PKCγ Antibody (Rabbit mAb) [F18C13]

CatNo: F6328

    Application: Reactivity:

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:30
    1:100
    1:200
    Application
    WB, IP, IHC, IF
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human, Mouse, Rat
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    78 kDa 80 kDa,36 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。

    Datasheet & SDS

    生物学的記述

    Specificity
    PKCγ Antibody (Rabbit mAb) [F18C13] detects endogenous levels of total PKCγ protein.
    Clone
    F18C13
    Synonym(s)
    PKCG, PRKCG, Protein kinase C gamma type, PKC-gamma
    Background
    PKCγ belongs to the conventional subgroup of the protein kinase C family, alongside PKCα and PKCβ, and is distinguished from other PKC isozymes by expression restricted almost entirely to the central nervous system, with particularly high abundance in cerebellar Purkinje cells. Like other conventional PKC isoforms, PKCγ is held in an autoinhibited, catalytically inactive state by a pseudosubstrate sequence that occupies the substrate-binding groove of the catalytic domain, and this autoinhibition is relieved when calcium and diacylglycerol engage the C2 and tandem C1A/C1B regulatory domains, respectively, releasing the pseudosubstrate and allowing the kinase domain to phosphorylate downstream target proteins. The great majority of pathogenic PRKCG variants causing spinocerebellar ataxia type 14 cluster within the C1A and C1B regulatory domains, with additional variants found in the C2 domain and, less frequently, in the catalytic domain itself, and biochemical characterization of C1A domain variants shows that they produce increased basal kinase activity while simultaneously becoming unresponsive to normal agonist-driven stimulation and relatively resistant to receptor-mediated downregulation, a pattern consistent with a leaky, partially deautoinhibited kinase rather than a simply hyperactive one. Functional testing of individual SCA14-associated mutations using Purkinje cell dendritic morphology as a live-cell readout of PKCγ biological activity shows that catalytic-domain mutations reliably produce increased biological activity in Purkinje cells, whereas mutations located within the regulatory C1 or C2 domains do not show this increased activity by the same dendritic-growth assay, despite several of these regulatory-domain mutations showing elevated enzymatic activity in isolated biochemical assays; this discrepancy indicates that regulatory-domain and catalytic-domain SCA14 mutations disrupt Purkinje cell function through mechanistically distinct routes rather than through a single, shared gain-of-function pathway. Independently of catalytic output, both wild-type and mutant PKCγ can form amyloid-like fibrils and aggregates in overexpression and reconstituted systems, and such aggregates are additionally detected in induced pluripotent stem cells derived from SCA14 patients and in primary Purkinje cell cultures, positioning PKCγ aggregation as a separate, mutation-associated pathological process running in parallel to altered catalytic regulation. PKCγ additionally functions in developmental synapse elimination, specifically pruning climbing fiber synapses from developing Purkinje cells, and disruption of this normal PKCγ-dependent pruning and dendritic development process by SCA14 mutations is directly implicated in the progressive cerebellar ataxia and Purkinje cell dysfunction characteristic of the disease.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください